1. Home
  2. ALGS vs TELA Comparison

ALGS vs TELA Comparison

Compare ALGS & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aligos Therapeutics Inc.

ALGS

Aligos Therapeutics Inc.

HOLD

Current Price

$6.03

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$0.78

Market Cap

31.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALGS
TELA
Founded
2018
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
31.4M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ALGS
TELA
Price
$6.03
$0.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$39.33
$2.00
AVG Volume (30 Days)
127.4K
294.8K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
88.30
37.59
EPS
N/A
N/A
Revenue
$2,186,000.00
$80,275,000.00
Revenue This Year
$32.20
$10.23
Revenue Next Year
$4.71
$14.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.84
52 Week Low
$3.98
$0.50
52 Week High
$13.69
$1.76

Technical Indicators

Market Signals
Indicator
ALGS
TELA
Relative Strength Index (RSI) 45.83 56.55
Support Level $4.80 $0.78
Resistance Level $6.91 $0.96
Average True Range (ATR) 0.56 0.08
MACD -0.12 0.01
Stochastic Oscillator 16.11 59.62

Price Performance

Historical Comparison
ALGS
TELA

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: